Recent News

• 12.09.2025 - Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium
• 11.25.2025 - Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health
• 11.13.2025 - More Than Just Risk: Genetic Testing Is Shaping Breast Cancer Treatment
• 11.11.2025 - Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
• 11.10.2025 - Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs
• 11.06.2025 - One Visit. Lasting Impact. – A MyRisk® Provider Story
• 11.06.2025 - Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference
• 11.03.2025 - Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution
• 10.31.2025 - New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner
• 10.27.2025 - Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025

Recent Filings

• 11.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.04.2025 - 8-K/A Current report
• 11.04.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.03.2025 - 8-K Current report
• 11.03.2025 - EX-99.1 EX-99.1
• 10.31.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.24.2025 - 4 Statement of changes in beneficial ownership of securities